The National Institutes of Health plans to complete in about a month its review of a petition that asks the government to march in on patents for the prostate cancer drug Xtandi. The decision will indicate whether the Biden administration is willing to use march-in rights to lower drug prices, and petition backers hope the decision opens the flood gates for more march-in petitions. Already, the Universities Allied for Essential Medicines, a global network of university students, submitted a request...